170 related articles for article (PubMed ID: 37432641)
1. Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial.
Koch EAT; Petzold A; Wessely A; Dippel E; Eckstein M; Gesierich A; Gutzmer R; Hassel JC; Knorr H; Kreuzberg N; Leiter U; Loquai C; Meier F; Meissner M; Mohr P; Pföhler C; Rahimi F; Schadendorf D; Schlaak M; Thoms KM; Ugurel S; Utikal J; Weichenthal M; Schuler-Thurner B; Berking C; Heppt MV
Front Med; 2023 Oct; 17(5):878-888. PubMed ID: 37432641
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis.
Koch EAT; Petzold A; Wessely A; Dippel E; Gesierich A; Gutzmer R; Hassel JC; Haferkamp S; Hohberger B; Kähler KC; Knorr H; Kreuzberg N; Leiter U; Loquai C; Meier F; Meissner M; Mohr P; Pföhler C; Rahimi F; Schadendorf D; Schell B; Schlaak M; Terheyden P; Thoms KM; Schuler-Thurner B; Ugurel S; Ulrich J; Utikal J; Weichenthal M; Ziller F; Berking C; Heppt MV; On Behalf Of The German Dermatologic Cooperative Oncology Group DeCOG Committee Ocular Melanoma
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34283061
[TBL] [Abstract][Full Text] [Related]
3. Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events.
Koch EAT; Petzold A; Dippel E; Erdmann M; Gesierich A; Gutzmer R; Hassel JC; Haferkamp S; Kähler KC; Kreuzberg N; Leiter U; Loquai C; Meier F; Meissner M; Mohr P; Pföhler C; Rahimi F; Schell B; Terheyden P; Thoms KM; Ugurel S; Ulrich J; Utikal J; Weichenthal M; Ziller F; Berking C; Heppt MV
Front Immunol; 2024; 15():1395225. PubMed ID: 38915414
[TBL] [Abstract][Full Text] [Related]
4. Clinical determinants of long-term survival in metastatic uveal melanoma.
Koch EAT; Petzold A; Wessely A; Dippel E; Erdmann M; Heinzerling L; Hohberger B; Knorr H; Leiter U; Meier F; Mohr P; Rahimi F; Schell B; Schlaak M; Terheyden P; Schuler-Thurner B; Ugurel S; Utikal J; Vera J; Weichenthal M; Ziller F; Berking C; Heppt MV
Cancer Immunol Immunother; 2022 Jun; 71(6):1467-1477. PubMed ID: 34709438
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity.
Koch EAT; Petzold A; Wessely A; Dippel E; Gesierich A; Gutzmer R; Hassel JC; Haferkamp S; Kähler KC; Knorr H; Kreuzberg N; Leiter U; Loquai C; Meier F; Meissner M; Mohr P; Pföhler C; Rahimi F; Schadendorf D; Schell B; Schlaak M; Terheyden P; Thoms KM; Schuler-Thurner B; Ugurel S; Ulrich J; Utikal J; Weichenthal M; Ziller F; Berking C; Heppt MV
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158786
[TBL] [Abstract][Full Text] [Related]
6. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG.
Franklin C; Mohr P; Bluhm L; Grimmelmann I; Gutzmer R; Meier F; Garzarolli M; Weichenthal M; Pfoehler C; Herbst R; Terheyden P; Utikal J; Ulrich J; Debus D; Haferkamp S; Kaatz M; Forschner A; Leiter U; Nashan D; Kreuter A; Sachse M; Welzel J; Heinzerling L; Meiss F; Weishaupt C; Gambichler T; Weyandt G; Dippel E; Schatton K; Celik E; Trommer M; Helfrich I; Roesch A; Zimmer L; Livingstone E; Schadendorf D; Horn S; Ugurel S
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688555
[TBL] [Abstract][Full Text] [Related]
7. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
[TBL] [Abstract][Full Text] [Related]
8. Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment.
Petzold A; Steeb T; Wessely A; Koch EAT; Vera J; Berking C; Heppt MV
Cancer Treat Rev; 2023 Apr; 115():102543. PubMed ID: 36931146
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
10. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study.
Heppt MV; Amaral T; Kähler KC; Heinzerling L; Hassel JC; Meissner M; Kreuzberg N; Loquai C; Reinhardt L; Utikal J; Dabrowski E; Gesierich A; Pföhler C; Terheyden P; Thoms KM; Zimmer L; Eigentler TK; Kirchberger MC; Stege HM; Meier F; Schlaak M; Berking C
J Immunother Cancer; 2019 Nov; 7(1):299. PubMed ID: 31722735
[TBL] [Abstract][Full Text] [Related]
11. Determinants of overall survival in patients with metastatic uveal melanoma.
Demkowicz P; Pointdujour-Lim R; Miguez S; Lee Y; Jones BSCL; Barker CA; Bosenberg M; Abramson DH; Shoushtari AN; Kluger H; Francis JH; Sznol M; Bakhoum MF
Cancer; 2023 Oct; 129(20):3275-3286. PubMed ID: 37382208
[TBL] [Abstract][Full Text] [Related]
12. Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM.
Placke JM; Kimmig M; Griewank K; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Welzel J; Engel DR; Kreft S; Sucker A; Lodde G; Krefting F; Stoffels I; Klode J; Roesch A; Zimmer L; Livingstone E; Hadaschik E; Becker JC; Weichenthal M; Tasdogan A; Schadendorf D; Ugurel S
EBioMedicine; 2023 Oct; 96():104774. PubMed ID: 37660535
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG.
Zaremba A; Mohr P; Gutzmer R; Meier F; Pföhler C; Weichenthal M; Terheyden P; Forschner A; Leiter U; Ulrich J; Utikal J; Welzel J; Kaatz M; Gebhardt C; Herbst R; Sindrilaru A; Dippel E; Sachse M; Meiss F; Heinzerling L; Haferkamp S; Weishaupt C; Löffler H; Kreft S; Griewank K; Livingstone E; Schadendorf D; Ugurel S; Zimmer L
Eur J Cancer; 2023 Jul; 188():140-151. PubMed ID: 37245442
[TBL] [Abstract][Full Text] [Related]
14. The Role of Immune Checkpoint Blockade in Uveal Melanoma.
Wessely A; Steeb T; Erdmann M; Heinzerling L; Vera J; Schlaak M; Berking C; Heppt MV
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013269
[TBL] [Abstract][Full Text] [Related]
15. Role of immune checkpoint inhibitors in metastatic uveal melanoma: a single-center retrospective cohort study.
Vanaken L; Woei-A-Jin FJSH; Van Ginderdeuren R; Deroose CM; Laenen A; Missotten G; Thal DR; Bechter O; Schöffski P; Clement P
Acta Oncol; 2023 May; 62(5):480-487. PubMed ID: 37200223
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients.
Leiter U; Loquai C; Reinhardt L; Rafei-Shamsabadi D; Gutzmer R; Kaehler K; Heinzerling L; Hassel JC; Glutsch V; Sirokay J; Schlecht N; Rübben A; Gambichler T; Schatton K; Pfoehler C; Franklin C; Terheyden P; Haferkamp S; Mohr P; Bischof L; Livingstone E; Zimmer L; Weichenthal M; Schadendorf D; Meiwes A; Keim U; Garbe C; Becker JC; Ugurel S
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093156
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of cutaneous and uveal melanoma liver metastases.
Hoefsmit EP; Rozeman EA; Van TM; Dimitriadis P; Krijgsman O; Conway JW; Pires da Silva I; van der Wal JE; Ketelaars SLC; Bresser K; Broeks A; Kerkhoven RM; Reeves JW; Warren S; Kvistborg P; Scolyer RA; Kapiteijn EW; Peeper DS; Long GV; Schumacher TNM; Blank CU
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33262254
[TBL] [Abstract][Full Text] [Related]
18. Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade.
Chorti E; Kowall B; Hassel JC; Schilling B; Sachse M; Gutzmer R; Loquai C; Kähler KC; Hüsing A; Gilde C; Thielmann CM; Zaremba-Montenari A; Placke JM; Gratsias E; Martaki A; Roesch A; Ugurel S; Schadendorf D; Livingstone E; Stang A; Zimmer L
Eur J Cancer; 2024 Mar; 200():113536. PubMed ID: 38306840
[TBL] [Abstract][Full Text] [Related]
19. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma.
Afzal MZ; Mercado RR; Shirai K
J Immunother Cancer; 2018 Jul; 6(1):64. PubMed ID: 29966520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
